HPLC purity
Reverse-phase HPLC with UV detection; ≥99% area purity target with related-substance reporting on request.
GLP-1 family · research-use
Semaglutide OEM supply.
Research use, worldwide.
Lyophilized semaglutide for research labs and private-label brand evaluation worldwide. ≥99% HPLC purity target, batch-linked COA, HPLC chromatogram and MS identity record.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework, with public comment open through 2026-06-29. Pending finalization, semaglutide cannot be compounded from bulk substances by US regulated bulk-substance facilities. Read the GLP-1 2026 update →
Lot SEM-5HPLC ≥ 99%MS confirmed2 / 5 / 10 / 15 mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Semaglutide |
|---|---|
| CAS number | 910463-68-2 |
| Class | GLP-1 receptor agonist (research) |
| Molecular weight | ≈ 4113.6 g/mol |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 2, 5, 10, 15, 20, 50 mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | 2–8 °C protected from light; long-term −20 °C |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
Semaglutide is off-patent in India and China as of 2026 — worldwide distribution and generic supply pathways are opening. All quotes require a destination country and buyer track.
Documentation
Batch documentation support for semaglutide lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the semaglutide reference profile.
Destination check
Buyer track and destination country reviewed against the FDA 2026 regulated bulk-substance bulks proposal before quoting.
FAQ
Semaglutide — frequently asked by B2B buyers.
Why is semaglutide marked research-use?
The FDA's 2026-04-30 proposal would remove GLP-1 medications, including semaglutide, from the regulatory bulk-substance framework, with public comment open through 2026-06-29. Pending finalization, US regulated bulk-substance facilities cannot compound semaglutide from bulk substances. Pepti positions semaglutide for research and private-label brand evaluation, worldwide rather than US regulated.
Is semaglutide off-patent in some countries?
Yes. Novo Nordisk's semaglutide patent expires in 2026 in several countries including India and China, opening worldwide distribution and generic supply pathways. We supply lyophilized semaglutide into compliant international markets.
Which markets do you serve for semaglutide?
India, Brazil, Mexico, Indonesia and select EMEA distributors with appropriate local registration; case-by-case review for other markets. Destination country is confirmed before quoting.
Can research labs source semaglutide?
Yes — lyophilized semaglutide is supplied for laboratory research with COA, HPLC, and MS documentation.
What does your COA report?
HPLC purity (target ≥99%), MS identity, water content, related-substance profile on request, and lot traceability tied to the document pack.
Related compounds